<DOC>
	<DOC>NCT01358929</DOC>
	<brief_summary>This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive multiple weekly subcutaneous doses of RO6870952. The anticipated time on study treatment is 8 weeks.</brief_summary>
	<brief_title>A Study of RO6807952 in Patients With Diabetes Mellitus Type 2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Adult patients, 18 to 70 years of age, inclusive Diagnosis of type 2 diabetes &gt;/=3 months and &lt;/=10 years prior to screening Fasting plasma glucose &gt;/=110 mg/dL and &lt;/=240 mg/dL Patients on a stable dose of metformin for at least 2 months prior to screening Hemoglobin HbA1c &gt;/=6.5% and &lt;/=10.5% Body mass index &gt;/=25 kg/m2 and &lt;/=42 kg/m2 Systolic blood pressure &lt;155 mmHg and diastolic blood pressure &lt;95 mmHg Patients with type 1 diabetes History of significant renal and hepatic diseases History of metabolic acidosis and diabetic gastroparesis History of pancreatitis History of coagulation disorders or unexplained excessive bleeding History of clinically significant cardiovascular disease or severe symptomatic hypoglycemia within 6 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>